atenolol has been researched along with Alloxan Diabetes in 16 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 7.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "To determine whether diabetes leads to retinal neuronal dysfunction in hypertensive transgenic (mRen-2)27 rats (Ren-2), and whether the effect can be prevented by treatment of hypertension with either the angiotensin-1 receptor blocker (AT1-RB) valsartan or the beta1-adrenergic receptor antagonist atenolol." | 3.74 | Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. ( Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL, 2007) |
| "Blockade of the renin-angiotensin system but not antihypertensive therapy with atenolol reduces vascular pathology in diabetic Ren-2 retina, suggesting that angiotensin II is a causative factor and therapeutic target in diabetic retinopathy." | 3.74 | Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. ( Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL, 2007) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 3.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "Metoprolol treatment produced a slight but significant reduction in serum glucose levels with elevation in serum insulin levels, while atenolol produced a slight increase in glucose levels but no effect on insulin levels." | 1.34 | Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. ( Bhadada, SV; Goyal, RK, 2007) |
| "Propranolol was found to exhibit a hypolipidemic effect in diabetic rats when administered alone or in combination with glibenclamide." | 1.29 | Studies on the glycemic and lipidemic effect of atenolol and propranolol in normal and diabetic rats. ( el Batran, S; Gaafar, K; Salama, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, RF | 1 |
| Bussey, CT | 1 |
| Mellor, KM | 1 |
| Cragg, PA | 1 |
| Lamberts, RR | 1 |
| Patel, BM | 1 |
| Bhadada, SV | 2 |
| Angulo, J | 1 |
| Wright, HM | 1 |
| Cuevas, P | 1 |
| González-Corrochano, R | 1 |
| Fernández, A | 1 |
| Cuevas, B | 1 |
| La Fuente, JM | 1 |
| Gupta, S | 1 |
| Sáenz de Tejada, I | 1 |
| Mabe, AM | 1 |
| Hoover, DB | 1 |
| Zhang, JZ | 1 |
| Gao, L | 1 |
| Widness, M | 1 |
| Xi, X | 1 |
| Kern, TS | 1 |
| Phipps, JA | 1 |
| Wilkinson-Berka, JL | 2 |
| Fletcher, EL | 1 |
| Tan, G | 1 |
| Jaworski, K | 1 |
| Ninkovic, S | 1 |
| Goyal, RK | 2 |
| Gaafar, K | 1 |
| Salama, S | 1 |
| el Batran, S | 1 |
| Bangaru, RA | 1 |
| Lakkad, NB | 1 |
| Rao, MV | 1 |
| Mitani, S | 1 |
| Okumura, K | 1 |
| Matsui, H | 1 |
| Toki, Y | 1 |
| Hashimoto, H | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Furman, BL | 2 |
| Tayo, FM | 2 |
| Mehvar, R | 1 |
| Nagamine, F | 1 |
| Murakami, K | 1 |
| Mimura, G | 1 |
| Sakanashi, M | 1 |
| Bailey, CJ | 1 |
| Thornburn, CC | 1 |
| Flatt, PR | 1 |
16 other studies available for atenolol and Alloxan Diabetes
| Article | Year |
|---|---|
β
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Dia | 2017 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling.
Topics: Animals; Atenolol; Benzopyrans; Blood Glucose; Blood Pressure; Cyclic GMP; Diabetes Mellitus, Experi | 2010 |
Remodeling of cardiac cholinergic innervation and control of heart rate in mice with streptozotocin-induced diabetes.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Atropine; Blood Glucose; Body Weight; Data Interpret | 2011 |
Captopril inhibits glucose accumulation in retinal cells in diabetes.
Topics: Adrenergic beta-Antagonists; Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2003 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically | 2007 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically | 2007 |
Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiov | 2007 |
Studies on the glycemic and lipidemic effect of atenolol and propranolol in normal and diabetic rats.
Topics: Animals; Atenolol; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Glyburide; Insulin; | 1994 |
Effect of chronic treatment with atenolol and prazosin in streptozotocin induced diabetic rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Diabetes Mellitus, Exp | 1996 |
Insulin alters cardiac muscle creatine kinase activity.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Creatine Kinase; Data Interpretation, | 2000 |
Effect of ICI 66082, a beta-adrenoceptor blocking drug on blood glucose in the rat.
Topics: Adipose Tissue; Animals; Atenolol; Blood Glucose; Diabetes Mellitus, Experimental; Glucose; Glyburid | 1975 |
Effect of experimental diabetes mellitus on the pharmacokinetics of atenolol enantiomers in rats.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Male; Ra | 1991 |
Effects of beta-adrenoceptor blocking agents on isolated atrial and papillary muscles from experimentally diabetic rats.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dose-Response Relati | 1989 |
Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.
Topics: Aging; Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experime | 1986 |
Proceedings: The hypoglycaemic action of ICI 66082 (4-(2-hydroxy-3-isopropyl-aminopropoxy) phenyl acetamide) in the rat.
Topics: Acetamides; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Diabetes Mellitus, Experi | 1974 |